论文部分内容阅读
糖尿病肾病患者57例。分为治疗组29例和对照组28例。两组患者均根据尿蛋白和肾功能的不同再分别分为早期肾病组、临床期肾功能正常组2个亚组。治疗组静注凯时10μg加入0.9%NaCl20ml,每日一次,连续14d。对照组不给上述治疗。控制血压、血脂、血糖等其他治疗方法各组相同。和对照组比较,治疗组患者尿总蛋白和尿白蛋白明显降低。静脉应用LipoPGE1治疗中早期糖尿病肾病,尿蛋白均明显减少,改善肾功能。
57 cases of diabetic nephropathy. Divided into treatment group 29 cases and control group 28 cases. Two groups of patients were divided into urinary protein and renal function were divided into early nephropathy group, clinical normal renal function in two subgroups. Treatment group intravenous Kai when 10μg 0.9% NaCl20ml, once daily for 14 days. The control group did not give the above treatment. Control of blood pressure, blood lipids, blood sugar and other treatments are the same in all groups. Compared with the control group, urinary total protein and urinary albumin in the treatment group decreased significantly. Intravenous LipoPGE1 in the treatment of early diabetic nephropathy, urinary protein were significantly reduced, improve renal function.